Antitumor effects of regorafenib and sorafenib in preclinical models of hepatocellular carcinoma

The purpose of this study was to investigate the antitumor activity of regorafenib and sorafenib in preclinical models of HCC and to assess their mechanism of action by associated changes in protein expression in a HCC-PDX mouse model. Both drugs were administered orally once daily at 10 mg/kg (rego...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncotarget
Hauptverfasser: Kissel, Maria, Berndt, Sandra, Fiebig, Lukas, Kling, Simon, Ji, Qunsheng, Gu, Qingyang, Lang, Tina, Hafner, Frank-Thorsten, Teufel, Michael, Zopf, Dieter
Format: Artigo
Sprache:Inglês
Veröffentlicht: Impact Journals LLC 2017
Schlagworte:
Research Paper
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5739799/
https://ncbi.nlm.nih.gov/pubmed/29291014
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.22334
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge